Selenium Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Selenium Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• It currently affects over one billion individuals worldwide, and this number could be increased to approximately 1.58 billion by 2025. [Khodadadi Homa (2025); evidence level 1]
• In addition to its widespread occurrence, hypertension is a key component of metabolic syndrome (MetS) and a risk factor for cardiovascular disease (CVD) related kidney disease, stroke, intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. [Khodadadi Homa (2025); evidence level 1]
• Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease. [Wu Xun (2026); evidence level 3]
• Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction. [Wu Xun (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For selenium blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Khodadadi Homa (2025). Dose-response association between circulating selenium and blood pressure: a systematic review and meta-analysis. DOI: 10.1186/s12889-025-24205-x. PMCID: PMC12625506. PMID: 41250018. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12625506/
• Wu Xun (2026). Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives. DOI: 10.3389/fmolb.2025.1699492. PMCID: PMC12883399. PMID: 41669146. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12883399/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.